Epidemiologic and clinical characteristics of pediatric SARS CoV2 infection

Page 1

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection

Dr. Mary H Lombardi – Dr. Andrea Campana

Lazio regional pediatric COVID center

Pediatric Multispecialty Unit

Emergency and General Pediatrics Department

Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

COVID-19 SYMPTOMS IN CHILDREN

(Garazzino et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020;25(18):pii=2000600. https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000600)

and clinical characteristics of pediatric SARS-CoV2 infection

2
Epidemiologic

COVID-19 SYMPTOMS IN CHILDREN

(Garazzino et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020;25(18):pii=2000600. https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000600)

and clinical characteristics of pediatric SARS-CoV2 infection

Epidemiologic
3

CHILDREN HOSPITALIZED WITH COVID

The majority of children (65.1%) were hospitalized

Hospital admission was inversely related to age (p < 0.01; Fisher exact test);

Children and COVID-19: State-Level Data Report (Sept 2021)

Epidemiologic and clinical characteristics
4
of pediatric SARS-CoV2 infection

CHILDREN HOSPITALAZED WITH COVID

However, some kids still do get admitted

Our experience:

OPBG – PALIDORO

Lazio Regional Pediatric COVID center

(16 march 2020 – 18 sept 2021)

 Total confirmed admitted pediatric cases  678

M/F = 1.18/1

Mean age 6,3 years (median 3,7)

Lazio -- Population 6 million Population < 20years --- 1 million

characteristics of pediatric SARS-CoV2 infection

Epidemiologic and
5
clinical

CHILDREN HOSPITALAZED WITH COVID

MMWR --- Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1255–1260. DOI: http://dx.doi.org/10.15585/mmwr.mm7036e2

and clinical characteristics of pediatric SARS-CoV2 infection

Epidemiologic
6

CHILDREN HOSPITALAZED WITH COVID

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 7 0 5 10 15 20 25 30 35 40 45 GI PNEUMONIA NEUTROPENIA MIO-PERICARDITIS MIS-C 31 PZ TOT: PICU 8: SURGICAL PROC. 14: SEIZURES 2: MONOCLONAL AB 6: REMDESEVIR

CHILDREN HOSPITALAZED WITH COVID

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 8 Age N° PTS COMPLICATIONS NO COMPL MINOR COMPL GI PULM MIS-C MYO-PERICARDITIS 0-1 216 126 80 1 5 2 6 2-6 175 115 30 8 14 6 6 7-10 75 49 7 12 6 6 6 11-14 88 45 11 14 10 12 16 >14 124 67 13 14 26 3 5 TOTAL 678 402 (59%) 141 49 61 29 39

CHILDREN HOSPITALAZED WITH COVID

Therapy

= Supportive

 Monitor vital signs, urine output, weight

 Fever control

 IV fluids

 Oxygen if needed

 Antibiotics only if you suspect an overinfection

 Anticoagulation only if risk factors

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 9

CHILDREN HOSPITALAZED WITH COVID

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 10 Age N° PTS COMPLICATIONS NO COMPL MINOR COMPL GI PULM MIS-C MYO-PERICARDITIS 0-1 216 126 80 1 5 2 6 2-6 175 115 30 8 14 6 6 7-10 75 49 7 12 6 6 6 11-14 88 45 11 14 10 12 16 >14 124 67 13 14 26 3 5 678 402 (59%) 141 49 61 29 39

MIS-C (Multisystem Inflammatory Syndrome in Children)

 Kids also get a hyper-inflammatory syndrome (MIS-C versus MIS-A)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 11

MIS-C (Multisystem Inflammatory Syndrome in Children)

Signs and Symptoms

- Unremitting fever

- Epidemiologic link to SARS-CoV-2(*)

- >/=2 of the following symptoms:

 Rash

 GI symptoms

 Peripheral edema

 Mucosal changes

 Conjunctivitis

 Lymphadenopathy

 Neurologic symptoms

NB: not necessarily positive swab

CRP > 5mg/dl

Lymphopenia (<1.000)

Thrombocytopenia (<150.000/mcL)

Neutrophilia

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 12
↑ Ferritin ↑ BNP/TPN, ↑ D-Dimers, ↑ LDH, ↑ triglycerides, ECG alterations
Positive
↓ Sodium ↓ Albumin
+/-
serology

MIS-C (Multisystem Inflammatory Syndrome in Children)

0-19 years (0-21 years)

 fever >3days (>24 hrs)

 Involvement of multiple systems (more systems)

 lab Inflammatory markers (defined)

 Other microbiologic causes excluded

 Evidence of SARS-CoV-2 infection (current or recent)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 13

MIS-C (Multisystem Inflammatory Syndrome in Children)

 Kids also get a hyper-inflammatory syndrome (MIS-C versus MIS-A)

 Pulmonary involvement is MILD in children

 Some degree of cardiac and/or intestinal involvement is almost always present

 Lab markers which correlate with the disease and severity (lymphopenia, ↑ CRP, ↓ albumin, ↑ D-dimer, ↑ Troponin and BNP)

 Important to quickly recognize the “cytokine storm” for a prompt diagnosis

 Treatment is most effective when started early

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 14

MIS-C (Multisystem Inflammatory Syndrome in Children)

Treatment - 1

IVIG: 2 g/kg in 12 h (or slower/divided doses if pump failure or electrolyte issues)

Methylprednisolone: 2mg/kg/day

In 2 divided doses OR

Methylprednisolone: 30 mg/kg (Max 1g) QD for 1-

3 days, then Methylprednisolone/Prednisone OR

If CNS involvement, consider Dexamethasone (10mg/m2/die)

IF PERSISTENCE, THEN CONSIDER

Anakinra ev: 2 mg/kg (max 100 mg) Q.I.D. or continuous IV (12 mg/kg die) (max 400mg/day)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 15
+

MIS-C (Multisystem Inflammatory Syndrome in Children)

Treatment - 2

+ supportive treatment

• Anticoagulation (prophylactic dosage)

• IV hydration / NPO

• Inotropes as needed

• Albumin / Furosemide as needed

• Electrolyte and fluid homeostasis

• (Antibiotics only if suspect superinfection)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 16

MIS-C (Multisystem Inflammatory Syndrome in Children)

Outcomes

 45 children admitted for MIS-C, followed up for 4-9 months

 76% required intensive care / 64% required vasopressors and/or inotropes.

 80% had some form of echocardiographic abnormalities (44% moderate-severe)

FOLLOW UP:

 By 1 to 4 weeks most inflammatory markers normalized, 32% persistent lymphocytosis

 By 1 to 4 weeks, only 18% had mild echocardiographic findings; all had normal coronaries.

 At 4 to 9 months, only 1 child had persistent mild dysfunction.

The majority of children with MIS-C present critically ill, but most inflammatory and cardiac manifestations go on to resolve within a few months.

17 Titolo Presentazione

MIS-C (Multisystem Inflammatory Syndrome in Children)

Why not so common in Asia?

 Different prevalence rates and different case fatality rates in different geographical areas

 Different ethnic or genetic background (HLA subtypes?)

 In New York Compared with White children:

 higher incidence of MIS-C among Black (IRR, 3.2; 95% CI, 2.04.9) and Hispanic (IRR, 1.7; 95% CI, 1.1-2.7) children

 no difference among Asian or Pacific Islander children (IRR, 0.9; 95% CI, 0.4-1.7)

 Also higher rate of admission for COVID

 Different SARS-CoV-2 subtypes

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 18

MIS-C (Multisystem Inflammatory Syndrome in Children)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 19
PERIOD TOT PTS ADMITT ED MEAN AGE MEDIA N AGE M/F MEA NLEN GTH OF STAY MEDIAN LENGTH OF STAY NEGATIVE ON D/C (N, %) COMPLICATIONS TOT PZ GI NEUTR OPENI PULM MIS-C MYOPERICARD 01/0331/05 53/56 7.56 7.02 31/22 10.2 7 31 (55.4%) 15 2 4 5 3 2 01/0631/08 40/42 4.91 2.22 17/23 6.7 4 11 (26.2%) 8 1 6 3 1 0 01/0931/10 110/116 4.78 1.38 66/44 5.6 4 23 (19.8%) 50 1 27 5 1 10 01/1130/11 58/61 5.47 1.53 35/23 5.02 4 9 (14.7%) 26 5 14 4 1 3 01/1231/12 48/56 6 5 26/22 6.2 4 25 (44.6%) 22 7 8 4 4 5 01/0131/01 57/63 7.95 8.36 26/31 6.1 4 19 (34.5%) 27 4 10 3 6 6 01/0228/02 35/49 6.33 4.55 14/21 5.74 4 11 (31.4%) 15 3 3 3 4 3 01/0331/03 64/72 8,09 8,07 34/30 5,55 3,5 15 (23,4%) 26 6 5 9 (3) 2 1 01/0430/04 61/71 6,04 3,53 30/31 3,5 3 19 (32,2%) 26 5 6 6 (1) 6 6 01/0531/05 33/37 5,59 3,59 16/17 3,94 3 16 (48,5%) 9 4 1 3 (1) 1 1 01/0630/06 19/26 6,6 3,25 10/9 6,05 6 7 (36,8%) 9 2 3 2 (0) 0 0 01/0731/07 33/40 6,66 3,91 18/15 5 3 14 (42,4%) 10 4 3 4 (0) 0 0 01/0831/08 48/58 5,6 2,58 30/18 4,04 3 11 (22,9%) 21 4 10 7 (1) 0 0 01/0918/09 19/24 6,75 4,41 3,47 3 4 (23,5%) 10 0 2 3 (0) 0 0

MIS-C (Multisystem Inflammatory Syndrome in Children)

Why not so common in Asia?

- Different prevalence rates and different case fatality rates in different geographical areas

- Different ethnic or genetic background (HLA subtypes?)

- Compared with White children

- higher incidence of MIS-C among Black (IRR, 3.2; 95% CI, 2.0-4.9) and Hispanic (IRR, 1.7; 95% CI, 1.1-2.7) children

- no difference among Asian or Pacific Islander children (IRR, 0.9; 95% CI, 0.4-1.7)

- Also higher rate of admission for COVID

- Different SARS-CoV-2 subtypes

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 20

Long-COVID IN CHILDREN

1355 children in schools in Switzerland

SCV2 seroprevalence + questionnaire

- 3% fatigue

- 2% difficulty concentrating

- 2% increased sleep

Overall 4% of the serology positive children had some symptoms above background rate lasting > 12 weeks (3 months)

*** 1 in 25 kids ***

11-17 year olds Cohort study of 3.000 positive kids and age/sex/geography matched controls

questionnaire

At 3 months post positive test 30% of kids had 3+ symptoms (versus 16% in controls)

Preprint ResSquare Sept 2021--- Stephenson

T, et al. Long COVID – the physical and mental health of children and nonhospitalised young people 3 months after SARS-CoV-2 infection; a national matched cohort study (The CLoCk study).

and clinical characteristics of pediatric SARS-CoV2 infection

Epidemiologic
21

COVID-19 MORTALITY N CHILDREN

Mortality (45 states, NYC, PR and GU reported)*

Among states reporting, children were 0.00%-0.25% of all COVID-19 deaths, and 7 states reported zero child deaths

In states reporting, 0.00%-0.03% of all child COVID-19 cases resulted in death

Children and COVID-19: State-Level Data Report (Sept 2021)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 22

THE SITUATION IN ITALY

(Source: EPICENTRO.ISS.IT The Italian Health Institute Epidemiology Center)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 23

EPIDEMIOLOGY IN KIDS V. ADULTS

 Why do kids get less sick than adults?

 What is the mechanism?

 Does infection determine persistent immunity in children? More so or less so than in adults?

Various hypotheses

 Different amount of expression of the 2 receptors (ACE and renin-angiotensin) in the upper airways (primary site of infection)

 Lower levels of IL-6, IL-10, myeloperoxidase, and P-selectine

 Possible protective role of pulmonary resident lymphocytes which interact between respiratory system and immune system

 Two studies found high titers of RSV- and mycoplasma IgG which might offer cross-protection towards SARS-CoV-2

 Possible cross-protection by routine childhood vaccines

Why COVID-19 is less frequent and severe in children: a narrative review; Reza Sinaei, Sara Pezeshki, Saeedeh Parvaresh, Roya Sinaei; Received: 19 May 2020 / Accepted: 8 September 2020 © Children’s Hospital, Zhejiang University School of Medicine 2020 World Journal of Pediatrics

characteristics of pediatric SARS-CoV2 infection

Epidemiologic
clinical
24
and

EPIDEMIOLOGY IN KIDS V. ADULTS

OPBG PALIDORO

(16 march 2020 – 18 sept 2021)

• Total confirmed admitted cases  678

• M/F = 1.18/1

• Total 771 admission

• Mean age 6,3 years (median 3,7)

• Contacts: 530 (78,2%)  history of contact with at least one known positive or suspected case (78,2%)

• Deaths in family or contacts: 14 (13 cases)

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 25

EPIDEMOLOGY TRANSMISSION

Attack rate of covid19 among close contacts

- Population based cohort study of contact tracing

- 730 index patients jan – july 2020

- 8852 close contacts

- Timeline

 Highest risk is 2 days prior and 3 days after onset of symptoms

 Mild/Mod symptomatic index case: 4.3 RR of infection compared to asymptomatic index case

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 26

EPIDEMIOLOGY TRANSMISSION IN CHILDREN

 Children play a large role in community transmission of multiple infectious pathogens. Interacting with children: inherent exposure to and risk of infectious diseases (parents, grandparents, daycare workers, teachers).,

 Household transmission dynamics: only 3.8% had a pediatric index case

Secondary infection rates of pediatric household contacts lower than adult

 Transmission in schools typically follows trends in community transmission, rather than preceding or augmenting them

 Increased risk of COVID-19 in kids attending school in person is lessened by layered prevention measures

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 27

EPIDEMIOLOGY TRANSMISSION IN CHILDREN

TRANSMISSION DEPENDS ON

 Do kids infect adults or do adults infect kids?

 Are kids a reservoir for infection now that adults are vaccinated?

 Exposure (duration, location, timing)

 Virus type/variant

 Donor Symptoms (type, severity, duration)

 Donor Viral load

 Donor Host factors (susceptibility and immune responses / vaccination status)

 Receiver Host factors

 What will happen with schools reopening ?

KIDS vs ADULTS

 more often asymptomatic,

 fewer symptoms, shorter duration

 Less symptomatic likely lower viral load

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 28

EPIDEMIOLOGY TRANSMISSION in

kids household contact

Cohort study of Children and transmission

6280 households with a pediatric index case

 27.3% experienced secondary transmission

Frequency of transmission was age-dependent

Age 0-3 -- (OR 1.43) versus reference 14-17 year-olds

Age 4-8 (OR 1.4)

Age 9-13 (OR 1.15)

 Younger children = higher odds of transmission

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 29

EPIDEMIOLOGY TRANSMISSION

Can we open schools safely?

Yes we can!

 Maximize vaccination levels among the adults in the school and parents particularly those in contact with young children

 Keep community transmission under control

 Layered prevention measures within the school and public transport

 Vaccinate children when possible

Epidemiologic and clinical characteristics of pediatric SARS-CoV2 infection 30

Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.